Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BMS, Tibotec combine HCV candidates for all oral direct-acting antiretroviral regimen

Executive Summary

Bristol-Myers Squibb Co. and Johnson & Johnson’s Tibotec Pharmaceuticals Ltd. (the infectious disease division of Janssen Pharmaceutical Co.’s Janssen Pharmaceuticals Inc.) have agreed to create an all-oral regimen for chronic hepatitis C by combining their Phase III direct-acting antiretrovirals: BMS’s daclatasvir (BMS790052) with Tibotec’s TMC435.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies